Wuhan YZY Biopharma Co Ltd
Company Profile
Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer, and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas. The company has designed and developed various clinical-stage candidate drug pipelines, such as M701 (EpCAM CD3 bispecific antibody), Y101D, Y150, Y2019 (RBD dimer subunit SARS-CoV-2 vaccine), M802, and Y400 (VEGFxANG2 bispecific antibody) for the treatment of different cancer and age-related complications. Geographically, the company derives all of its revenue from the People's Republic of China (PRC).
Contact
No. 666 Gaoxin Road
Building C2-1, Guanggu Biocity
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHNT: +86 2782668988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
106
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,321.10 | 10.80 | -0.12% |
CAC 40 | 8,229.49 | 29.37 | -0.36% |
DAX 40 | 24,322.75 | 7.28 | -0.03% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,489.53 | 62.54 | 0.66% |
HKSE | 25,807.71 | 219.84 | -0.84% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
SSE Composite Index | 3,913.76 | 2.57 | -0.07% |